Age Related Macular Degeneration Amd Market Overview
The global Age Related Macular Degeneration Amd market was valued at USD 11.3 billion in 2024 and is expected to grow from USD 11.8 billion in 2025 to USD 18.0 billion by 2035, registering a CAGR of 4.4% during the forecast period from 2026 to 2035. The rising elderly population, increasing prevalence of AMD, growing awareness and screening, advances in treatment options, and increasing healthcare expenditure are supporting market growth.
North America is expected to remain the dominant regional market, with its market value projected to increase from USD 4.0 billion in 2024 to USD 6.0 billion by 2035. The market is also benefiting from technological advances in anti-VEGF therapies and gene therapy, while Asia Pacific is emerging as an important growth region because of its aging population, increasing awareness, and improving access to eye-care services.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/age-related-macular-degeneration-amd-market
Key Companies in the Age Related Macular Degeneration Amd Market
Novartis
Bayer
Pfizer
Iveric Bio
Eyenovia
Roche
Santen Pharmaceutical
Horizon Therapeutics
Apellis Pharmaceuticals
Amgen
Genentech
AbbVie
Regeneron Pharmaceuticals
NantKwest
The market is being driven by the growing burden of age-related vision impairment and the expanding elderly population worldwide. Advances in retinal therapies, including anti-VEGF treatments and emerging gene-therapy approaches, are improving the treatment landscape. Increasing awareness and screening programs are encouraging earlier diagnosis, while developments in telemedicine and genetic testing are creating additional opportunities for patient monitoring and personalized treatment.
The Age Related Macular Degeneration Amd Market is segmented by type, diagnosis method, treatment type, distribution channel, and region. By type, the market includes Dry AMD, Wet AMD, and Geographic Atrophy. Diagnosis methods include Visual Acuity Test, Optical Coherence Tomography, Fundus Photography, and Fluorescein Angiography. Treatment types comprise Anti-VEGF Injections, Photodynamic Therapy, Nutritional Supplements, and Laser Surgery, while distribution channels include Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Recent Developments and Market Trends:
Roche announced a strategic collaboration with Apellis Pharmaceuticals in March 2025 to co-develop and commercialize complement pathway inhibitors for geographic atrophy.
Novartis announced a licensing and distribution agreement with Santen Pharmaceutical in June 2025 to expand access to anti-VEGF therapies in selected Asian markets.
Iveric Bio reached a product-launch milestone in selected European countries in January 2025 for its geographic atrophy treatment program.
Anti-VEGF therapies and emerging gene-therapy approaches are continuing to transform treatment options for patients with AMD.
Advanced retinal imaging and diagnostic technologies are improving disease detection and supporting more personalized treatment decisions.
Telemedicine and genetic testing are emerging as important opportunities for improving AMD screening, monitoring, and individualized care.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Age Related Macular Degeneration Amd Market through 2035.
Analyze key segments based on disease type, diagnosis method, treatment type, distribution channel, and region.
Evaluate regional opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify major companies and understand their competitive positioning in the global AMD market.
Assess the impact of population aging, disease prevalence, advanced therapies, and increasing screening on market growth.
Understand emerging opportunities associated with gene therapy, retinal imaging, telemedicine, and genetic testing.
Future Outlook:
The global Age Related Macular Degeneration Amd Market is expected to maintain steady growth through 2035 as population aging and the prevalence of AMD continue to increase. Advances in anti-VEGF therapies, gene therapy, retinal imaging, and personalized treatment approaches are expected to create sustained opportunities. Growing awareness, improved screening, expanding healthcare access, and the increasing adoption of telemedicine and genetic testing are also likely to strengthen the market’s long-term development.
➤➤Explore Our Latest Related Reports:
